GE HealthCare’s Photonova Spectra photon-counting CT receives FDA clearance

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Very Positive)

Key Terms

510(k) clearance regulatory

A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.

photon-counting CT medical

Photon-counting CT is an advanced form of CT scan that detects and counts individual X-ray particles rather than measuring them as a single combined signal, producing clearer images with finer detail and better ability to tell different materials apart. For investors, it matters because the technology can improve diagnostic accuracy, reduce repeat scans and radiation exposure, and open new clinical uses—factors that can drive demand for upgraded scanners, affect hospital purchasing, and influence reimbursement and revenue for medical-imaging suppliers.

computed tomography medical

Computed tomography (CT) is an imaging method that uses X-rays taken from multiple angles and computer processing to produce detailed cross‑sectional pictures of the body, like slicing a loaf of bread to see inside. Investors care because CT machines and their software are significant revenue drivers for medical device makers and hospitals, influence diagnostic speed and accuracy, and face regulatory, reimbursement, and technological risk that can affect company earnings.

spectral imaging medical

Spectral imaging is a camera-based technique that captures light across many wavelengths—beyond the colors our eyes see—to reveal chemical makeup, tissue differences or material properties that ordinary photos miss. For investors, it matters because these deeper visuals can enable earlier disease detection, better product inspection, or new sensing services, acting like a fingerprint reader for materials that can create competitive products, regulatory advantages, or new revenue streams.

GPU technical

A GPU (graphics processing unit) is a specialized computer chip designed to handle many calculations at once, originally for rendering images and video but now widely used for tasks like artificial intelligence, data analysis and high-performance computing. Investors watch GPU demand and prices because strong sales often signal growth for chip makers and their customers, affect profit margins and capital spending, and can forecast wider trends in gaming, AI adoption and cloud services.

accelerated computing technical

Accelerated computing involves using specialized hardware, like graphics processors or other accelerators, to perform certain tasks much faster than traditional computers. This speeds up complex calculations, making processes more efficient and enabling faster decision-making. For investors, it means technological advancements that can improve the performance of data analysis, artificial intelligence, and other demanding applications, potentially leading to better business outcomes and competitive advantages.

restricted stock units financial

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

employee stock option financial

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

03/23/2026 - 09:59 AM

FDA clearance quickly follows Photonova Spectra’s debut at the Radiological Society of North America (RSNA) 2025 Annual Meeting, marking rapid momentum for GE HealthCare’s innovative photon-counting CT technology
Photonova Spectra introduces the next generation of spectral photon-counting CT technology with 8‑bin energy resolution, powered by GE HealthCare’s proprietary Deep Silicon detector technology and a one‑scan universal workflow designed to boost efficiency and reduce complexity across a wide range of CT exams
Photonova Spectra is a result of the company’s $5.1 billion innovation investment, leading to a wave of transformational products across the portfolio which combined are expected to drive 1-2% revenue growth

CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Photonova™ Spectra,ⁱ an innovative photon‑counting computed tomography (PCCT) solution powered by the company’s novel Deep Silicon detector technology and offered as a flexible platform with multiple configurations to meet diverse clinical needs. With wide coverage and the combination of ultra-high definition (UHD) spatial and spectral imaging, Photonova Spectra helps enable fast acquisition speeds and the precise visualization of subtle tissue variations, small lesions and vascular structures.

GE HealthCare’s Photonova Spectra photon-counting CT receives FDA clearance

Photon-counting CT represents a significant advancement in medical imaging. Unlike conventional CT systems – which first convert X-ray photons into visible light before measuring them – photon-counting CT directly counts individual photons and measures their energy. This approach enables higher spectral and spatial resolution as well as improved tissue characterization, helping provide clinicians with rich information to detect and diagnose disease with confidence.

“As clinicians across the United States face rising volumesⁱⁱ and increasing diagnostic complexity, ⁱⁱⁱ technology must do more than capture images; it must simplify decision-making and strengthen performance across the enterprise,” says Catherine Estrampes, President & CEO, U.S. and Canada, GE HealthCare. “Photonova Spectra is designed to deliver rich clinical insights in every scan and help alleviate cognitive burden for care teams. With the U.S. 510(k) clearance, we are proud to now bring this innovation to U.S. healthcare systems and the patients they serve.”

Today, Photonova Spectra stands out with the introduction of Deep Silicon, a novel detector material designed to enhance spectral imaging performance. Leveraging the purity and structural consistency of silicon – a high-performing semiconductor material – Deep Silicon enables the precise measurement of photon energy and delivers high levels of energy resolution, which are critical for advanced image reconstruction. This capability can allow clinicians to obtain spectral images with high levels of contrast, combined with detailed visualization across neurological, oncological, musculoskeletal, thoracic, and cardiac imaging.

Furthermore, Deep Silicon with 8-bin energy resolution supports advanced material separation and characterization capabilities. This enables Photonova Spectra to clearly distinguish between different materials such as iodine, calcium and fat with remarkable precision. Its wide detector coverage and rapid rotation speed (0.23 seconds) also support fast acquisition and motion-free imaging – even in challenging patient scenarios.

Photonova Spectra automatically captures both 8-bin spectral and ultra-high definition spatial data simultaneously, without special setup or multiple protocols. This design gives clinicians access to spectral information in every exam, supporting confident decision-making and treatment monitoring in complex cases across specialties.

“Elevating diagnostic confidence, particularly with subtle low-contrast structures, requires increasing clarity significantly to facilitate enhanced material differentiation,” shares Giuseppe Toia, MD, Assistant Professor of Radiology, Associate Section Chief of Abdominal Imaging and Intervention and CT Modality Chief with the Department of Radiology at the University of Wisconsin School of Medicine and Public Health. “Being involved in developing and testing the Deep Silicon detector has allowed us to see what this technology is capable of. During evaluative studies, this system allowed us to extract more clinically actionable information from a single scan to support informed decisions for research and clinical care. Because photon counting CT is a fundamentally different approach to imaging, we find it results in clean spectral signatures, high spatial resolution and accurate CT numbers.”

To process the increased data volumes produced by photon‑counting CT, Photonova Spectra incorporates NVIDIA accelerated computing technology. Designed to handle up to 50 times more data than conventional CT,^iv the GPU‑powered architecture is intended to help maintain smooth, efficient workflows by leveraging NVIDIA’s high-performance computing platform and CUDA-optimized reconstruction to turn massive spectral datasets into timely, clinically actionable images.

Workflow efficiency is further supported by a one‑scan, universal full‑fidelity approach intended to reduce exam‑specific protocols and enable automated reconstruction of ultra‑high definition spectral images on demand. The CT ONE operator environment and automated features — including Auto Positioning — are designed to help improve consistency across GE HealthCare systems and simplify the overall CT process.

Altogether, Photonova Spectra’s advanced architecture offers new opportunities for research in quantitative imaging, tissue characterization, and spectral biomarker discovery. To this end, GE HealthCare is collaborating with leading healthcare institutions across the United States to explore novel clinical applications and imaging protocols previously constrained by conventional CT technology:

UW–Madison (Madison, Wisconsin): Represents the first U.S. clinical evaluation site of GE HealthCare’s silicon based photon-counting CT, where researchers explore continuous improvement opportunities, such as elevating image quality, reducing noise and motion artifacts, enhancing soft tissue contrast, and exploring new clinical applications across oncology, cardiology, neurology and other CT intensive specialties.
Stanford Medicine (Palo Alto, California): Concentrates on both human subject and technical research efforts – specifically assessing reconstruction methods, optimizing image presentation workflows, and identifying potential pathology specific advantages such as ultra-high-resolution structural visualization, improved tissue characterization, and potential new biomarkers.

“Photonova Spectra reflects years of intentional design and close collaboration with clinicians, researchers and collaborators across the globe,” adds Jean-Luc Procaccini, President & CEO, Molecular Imaging and Computed Tomography, GE HealthCare. “From the earliest stages to today, we remain focused on building a system that addresses the practical realities of clinical practice while opening pathways for scientific advancement. The result is a photon-counting platform engineered for the needs of today’s care teams, as well as the imaging challenges and research opportunities that will shape the future of CT.”

Leveraging GE HealthCare’s platform architecture, Photonova Spectra also is purposefully designed for easy install and to fit into existing GE HealthCare CT ready rooms with minimal changes, preserving the foundational mechanical, electrical, and workflow design used across the Revolution family.

With U.S. FDA 510(k) clearance now achieved, GE HealthCare will begin preparing for commercial availability in the United States.

News of Photonova Spectra’s 510(k) clearance quickly follows GE HealthCare’s unveiling of the technology at the Radiological Society of North America (RSNA) Annual Meeting in November 2025 – demonstrating the company’s ability to move innovative technology from introduction to regulatory validation with speed and discipline.

For more information on GE HealthCare’s Photonova Spectra photon-counting CT system, visit gehealthcare.com.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.

ⁱ Photonova Spectra is 510(k) cleared with the U.S. FDA. Not CE Marked. Not available for sale in Europe, Canada, or any other region.
ⁱⁱ Kaufman Hall. State of Hospital Volumes. Kaufman Hall, https://www.kaufmanhall.com/insights/infographic/state-hospital-volumes. Accessed October 6, 2025.
ⁱⁱⁱ Sittig, Dean F., and Hardeep Singh. A New Socio-technical Model for Studying Health Information Technology in Complex Adaptive Healthcare Systems. In: Henriksen K, Battles JB, Keyes MA, Grady ML, editors. Advances in Patient Safety: New Directions and Alternative Approaches (Vol. 1: Assessment). Rockville (MD): Agency for Healthcare Research and Quality (US); August 2008. https://www.ncbi.nlm.nih.gov/books/NBK338593/. Accessed October 6, 2025.
^iv When compared to Revolution Apex Elite.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260323095678/en/

GE HealthCare Media Contact

Margaret Steinhafel

M +1 608 381 8829

margaret.steinhafel@gehealthcare.com

Source: GE HealthCare

GE HealthCare’s Photonova Spectra photon-counting CT receives FDA clearance

Key Terms

NASDAQ:GEHC

GEHC Rankings

GEHC Latest News

GEHC Latest SEC Filings

GEHC Stock Data

GE HealthCare’s Photonova Spectra photon-counting CT receives FDA clearance

Key Terms

NASDAQ:GEHC

GEHC Rankings

GEHC Latest News

GEHC Latest SEC Filings

GEHC Stock Data

Related Articles